For example, we are currently executing a full-service trial for treatment of multiple system atrophy, a severe degenerative neurological disorder affecting the body's involuntary functions. We are deploying a full suite of capabilities, including e-coa, e-consent, and home research nurses on this study to significantly reduce the travel burden on these patients who have significant mobility challenges.

Feb 15, 2022 / CEO / receipt, needs a key / Ari Goosby, CEO | earnings call 2022-02-15 | transcript baf88bff-1514-4641-99c2-04095b4101f6 | chars 9610-10016 | segment 9